Innovating Works

I.O.V.

DEFINITIVE: Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer ISTITUTO ONCOLOGICO VENETO participó en un HORIZON EUROPE HORIZON-MISS-2023-CANCER-01 HER2+ breast cancer affects around 390.000 women annually worldwide (i.e. 3 patients every 4 minutes). Over the last decade, polychemotherap...
2023-12-11 - 2028-11-30 | Financiado
RealHOPE: Real World Handling of Protein Drugs Exploration Evaluation and Education ISTITUTO ONCOLOGICO VENETO participó en un H2020 H2020-JTI-IMI2-2020-20-two-stage RealHOPE will create an understanding of the real-life handling of protein drugs in hospital pharmacy, clinics and in the hands of patients...
2021-07-05 - 2025-06-30 | Financiado
CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... ISTITUTO ONCOLOGICO VENETO participó en un FP7 Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
Financiado
CTCTRAP: Circulating Tumor Cells TheRapeutic APheresis a novel biotechnology enabling personalized therapy f... ISTITUTO ONCOLOGICO VENETO participó en un FP7 "Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven...
Financiado
TRANS-INT: New Oral Nanomedicines Transporting Therapeutic Macromolecules across the Intestinal Barrier ISTITUTO ONCOLOGICO VENETO participó en un FP7 Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies hav...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.